March 25, 2021 -- A new study published in Nature Communications found that intratumoral PVSRIPO therapy through unique activation of antigen-presenting cells in the tumor microenvironment stimulates functional CD8+ T-cell responses, leading to systemic antitumor immunity.
PVSRIPO is an investigational immunotherapy based on the live-attenuated Sabin type 1 poliovirus vaccine developed by Istari Oncology. PVSRIPO has a distinct target (the poliovirus receptor CD155), which is widely expressed in neoplastic cells of most solid tumors.
According to the preclinical data, PVSRIPO triggers sustained type 1/III interferon secretion with minimal release of unwanted cytokines.
The company is preparing to evaluate PVSRIPO in a phase II clinical study to determine its ability to generate a systemic immune response in melanoma tumors and suppress cancer growth.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
